Comparative Pharmacology
Head-to-head clinical analysis: KERLEDEX versus OPHTHOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERLEDEX versus OPHTHOCORT.
KERLEDEX vs OPHTHOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Kerledex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
OPHTHOCORT contains chloramphenicol, a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation; and hydrocortisone, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
Intravenous: 500 mg every 6 hours; Oral: 250 mg every 8 hours.
One drop into the affected eye(s) every 3-4 hours, or more frequently as needed. In severe cases, one drop every hour. Shake well before use.
None Documented
None Documented
Terminal half-life 12 hours (range 10–14) in normal renal function; extended to 30–50 hours in severe renal impairment (CrCl <30 mL/min); 6–8 hours in hepatic cirrhosis.
Terminal elimination half-life: 2.5-3.5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70% unchanged; fecal/biliary: 20% as metabolites; 10% as minor metabolites. Total renal clearance 180 mL/min, active tubular secretion accounts for 60% of renal elimination.
Renal (70-80% as unchanged drug), fecal (15-20% via biliary elimination), with minor metabolic clearance.
Category C
Category C
Corticosteroid/Antibiotic Combination
Ophthalmic Corticosteroid/Antibiotic Combination